Multi-center, Randomized, Open-label, Parallel-Arm, Single-dose, Pharmacokinetic Study of rVIIa-FP (CSL689) in Subjects With Congenital Factor VII Deficiency
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs CSL 689 (Primary) ; Eptacog alfa
- Indications Factor-VII-Deficiency
- Focus Pharmacokinetics
- Sponsors CSL Behring
- 17 Nov 2016 Status changed from active, no longer recruiting to completed.
- 13 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 13 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.